Compare FLL & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLL | OTLK |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.7M | 92.8M |
| IPO Year | 1993 | 2016 |
| Metric | FLL | OTLK |
|---|---|---|
| Price | $2.88 | $2.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $5.00 | $4.00 |
| AVG Volume (30 Days) | 160.2K | ★ 3.4M |
| Earning Date | 11-06-2025 | 12-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $299,916,000.00 | $1,505,322.00 |
| Revenue This Year | $4.94 | N/A |
| Revenue Next Year | $7.83 | $342.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $2.25 | $0.79 |
| 52 Week High | $5.59 | $3.39 |
| Indicator | FLL | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 68.72 |
| Support Level | $2.61 | $1.91 |
| Resistance Level | $3.25 | $2.10 |
| Average True Range (ATR) | 0.18 | 0.16 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 52.84 | 93.28 |
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.